119 related articles for article (PubMed ID: 38932360)
1. Risk of Post-COVID-19 Uveitis and Risk Modification by Vaccination: A Nationwide Retrospective Cohort Study.
Kim J; Ahn SJ
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932360
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
Kim J; Kwon HY; Ahn SJ
JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
[TBL] [Abstract][Full Text] [Related]
3. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database.
Kumar A; Miller DC; Sun Y; Arnold BF; Acharya NR
Ophthalmology; 2023 Dec; 130(12):1269-1278. PubMed ID: 37480943
[TBL] [Abstract][Full Text] [Related]
4. Noninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study.
Chang MS; Kim HR; Kim S; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
Am J Ophthalmol; 2024 Feb; 258():22-31. PubMed ID: 37739204
[TBL] [Abstract][Full Text] [Related]
5. Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study.
Kim HR; Kim S; Chang MS; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
Am J Ophthalmol; 2024 Jun; 262():125-133. PubMed ID: 38341167
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Medications and COVID-19 Outcomes in Patients with Noninfectious Uveitis in the Era of COVID-19 Vaccinations.
Sechrist SJ; Tang E; Sun Y; Arnold BF; Acharya NR
Ophthalmol Sci; 2024; 4(2):100411. PubMed ID: 38146526
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
[TBL] [Abstract][Full Text] [Related]
8. Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database.
Sun Y; Miller DC; Akpandak I; Chen EM; Arnold BF; Acharya NR
Ophthalmology; 2022 Oct; 129(10):1096-1106. PubMed ID: 35588945
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records.
Hsieh TYJ; Chang R; Yong SB; Liao PL; Hung YM; Wei JC
Diabetes Care; 2023 Dec; 46(12):2193-2200. PubMed ID: 37851392
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
11. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study.
Wu JT; La J; Branch-Elliman W; Huhmann LB; Han SS; Parmigiani G; Tuck DP; Brophy MT; Do NV; Lin AY; Munshi NC; Fillmore NR
JAMA Oncol; 2022 Feb; 8(2):281-286. PubMed ID: 34854921
[TBL] [Abstract][Full Text] [Related]
12. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
13. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
Mizrahi B; Sudry T; Flaks-Manov N; Yehezkelli Y; Kalkstein N; Akiva P; Ekka-Zohar A; Ben David SS; Lerner U; Bivas-Benita M; Greenfeld S
BMJ; 2023 Jan; 380():e072529. PubMed ID: 36631153
[TBL] [Abstract][Full Text] [Related]
14. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
Molteni E; Canas LS; Kläser K; Deng J; Bhopal SS; Hughes RC; Chen L; Murray B; Kerfoot E; Antonelli M; Sudre CH; Pujol JC; Polidori L; May A; Hammers PA; Wolf J; Spector PTD; Steves CJ; Ourselin PS; Absoud M; Modat M; Duncan PEL
Lancet Reg Health Eur; 2022 Aug; 19():100429. PubMed ID: 35821715
[TBL] [Abstract][Full Text] [Related]
15. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
16. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection.
Malden DE; Liu IA; Qian L; Sy LS; Lewin BJ; Asamura DT; Ryan DS; Bezi C; Williams JTB; Kaiser R; Daley MF; Nelson JC; McClure DL; Zerbo O; Henninger ML; Fuller CC; Weintraub ES; Saydah S; Tartof SY
Nat Commun; 2024 May; 15(1):4101. PubMed ID: 38778026
[TBL] [Abstract][Full Text] [Related]
17. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
[TBL] [Abstract][Full Text] [Related]
18. Retinal Artery and Vein Occlusion Risks after Coronavirus Disease 2019 or Coronavirus Disease 2019 Vaccination.
Park HS; Lee NK; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
Ophthalmology; 2024 Mar; 131(3):322-332. PubMed ID: 37739232
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
medRxiv; 2021 Oct; ():. PubMed ID: 34642696
[TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
